Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

SIMPLE SUMMARY: Several studies have demonstrated that gemtuzumab ozogamicin (GO) improves outcomes with intensive chemotherapy in some adults with acute myeloid leukemia (AML), but it has remained unclear which dosing schedule of GO is best. Here, we conducted a phase 1/2 study in 66 adults with ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Godwin, Colin D., Rodríguez-Arbolí, Eduardo, Othus, Megan, Halpern, Anna B., Appelbaum, Jacob S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Oehler, Vivian G., Keel, Siobán B., Abkowitz, Janis L., Cooper, Jason P., Cassaday, Ryan D., Estey, Elihu H., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221325/
https://www.ncbi.nlm.nih.gov/pubmed/35740603
http://dx.doi.org/10.3390/cancers14122934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221325/
https://www.ncbi.nlm.nih.gov/pubmed/35740603
http://dx.doi.org/10.3390/cancers14122934

Ejemplares similares